Background: Malignant pleural mesothelioma is a pathology with no effective therapy and a poor prognosis. Our previous study demonstrated an in vitro inhibitory effect on mesothelioma cell lines of both the lysate and secretome of adipose tissue-derived Mesenchymal Stromal Cells. The inhibitory activity on tumor growth has been demonstrated also in vivo: five million Mesenchymal Stromal Cells, injected "in situ", produced a significant therapeutic efficacy against MSTO-211H xenograft equivalent to that observed after the systemic administration of paclitaxel. Objective: The objective of this study is to evaluate the efficacy of less (half a million) Mesenchymal Stromal Cells and micro-fragmented adipose tissues (the biological tissue from which the Mesenchymal Stromal Cells were isolated) on mesothelioma cells growth. Methods: Tumor cells growth inhibition was evaluated in vitro and in a xenograft model of mesothelioma. Results: The inhibitory effect of micro-fragmented fat from adipose-tissue has been firstly confirmed in vitro on MSTO-211H cell growth. Then the efficacy against the growth of mesothelioma xenografts in mice of both micro-fragmented fat and low amount of Mesenchymal Stromal Cells has been evaluated. Our results confirmed that both Mesenchymal Stromal Cells and micro-fragmented fat, injected "in situ", did not stimulate mesothelioma cell growth. By contrast, micro-fragmented fat produced a significant inhibition of tumor growth and progression, comparable to that observed by the treatment with paclitaxel. Low amount of Mesenchymal Stromal Cells exerted only a little anticancer activity. Conclusion: Micro-fragmented fat inhibited mesothelioma cell proliferation in vitro and exerted a significant control of the mesothelioma xenograft growth in vivo.
Micro-Fragmented Fat Inhibits the Progression of Human Mesothelioma Xenografts in Mice / S. La Monica, V. Cocce, M. Bonelli, G. Alessandri, R. Alfieri, C.A. Lagrasta, C. Frati, L. Flammini, A. Gianni, F. Petrella, F. Paino, A. Pessina. - In: CURRENT CANCER DRUG TARGETS. - ISSN 1568-0096. - 23:(2023), pp. 1-6. [Epub ahead of print] [10.2174/1568009623666230201092302]
Micro-Fragmented Fat Inhibits the Progression of Human Mesothelioma Xenografts in Mice
V. CocceSecondo
;A. Gianni;F. Petrella;F. PainoPenultimo
;A. PessinaUltimo
2023
Abstract
Background: Malignant pleural mesothelioma is a pathology with no effective therapy and a poor prognosis. Our previous study demonstrated an in vitro inhibitory effect on mesothelioma cell lines of both the lysate and secretome of adipose tissue-derived Mesenchymal Stromal Cells. The inhibitory activity on tumor growth has been demonstrated also in vivo: five million Mesenchymal Stromal Cells, injected "in situ", produced a significant therapeutic efficacy against MSTO-211H xenograft equivalent to that observed after the systemic administration of paclitaxel. Objective: The objective of this study is to evaluate the efficacy of less (half a million) Mesenchymal Stromal Cells and micro-fragmented adipose tissues (the biological tissue from which the Mesenchymal Stromal Cells were isolated) on mesothelioma cells growth. Methods: Tumor cells growth inhibition was evaluated in vitro and in a xenograft model of mesothelioma. Results: The inhibitory effect of micro-fragmented fat from adipose-tissue has been firstly confirmed in vitro on MSTO-211H cell growth. Then the efficacy against the growth of mesothelioma xenografts in mice of both micro-fragmented fat and low amount of Mesenchymal Stromal Cells has been evaluated. Our results confirmed that both Mesenchymal Stromal Cells and micro-fragmented fat, injected "in situ", did not stimulate mesothelioma cell growth. By contrast, micro-fragmented fat produced a significant inhibition of tumor growth and progression, comparable to that observed by the treatment with paclitaxel. Low amount of Mesenchymal Stromal Cells exerted only a little anticancer activity. Conclusion: Micro-fragmented fat inhibited mesothelioma cell proliferation in vitro and exerted a significant control of the mesothelioma xenograft growth in vivo.File | Dimensione | Formato | |
---|---|---|---|
BMS-CCDT-2022-238-MS.pdf
Open Access dal 01/03/2024
Tipologia:
Post-print, accepted manuscript ecc. (versione accettata dall'editore)
Dimensione
4.06 MB
Formato
Adobe PDF
|
4.06 MB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.